Summary of Product Characteristics last updated on the eMC: 03/07/ Palifermin is a human keratinocyte growth factor (KGF), produced by. Background. Kepivance is a recombinant human keratinocyte growth factor that works at the cellular level to Kepivance [package insert]. This page contains brief information about palifermin and a collection of links to more information about the use of this drug, research results.
|Published (Last):||10 May 2005|
|PDF File Size:||20.19 Mb|
|ePub File Size:||8.49 Mb|
|Price:||Free* [*Free Regsitration Required]|
Patients who have received a prescription of this drug for a condition other than which it is approved may wish to discuss this issue with their physician.
Kepivance Effective in Managing Mucositis in Patients Undergoing Chemotherapy
Fda medwatch july safety labeling changes includes Are there any special precautions patients should be aware of before starting treatment? In kepigance and rats, Kepivance enhanced proliferation of epithelial cells as measured by Ki67 immunohistochemical staining and BrDU uptake and demonstrated an jnsert in tissue thickness of the tongue, buccal mucosa, and gastrointestinal tract. Additionally, the observed incidence of antibody positivity in an assay may be influenced by several factors including sample handling, timing of sample collection, concomitant medications and underlying disease.
However, use of Kepivance in pediatric patients ages 1 to 16 years is supported by evidence from adequate and well-controlled studies of Kepivance in adults and a phase 1 ineert that included 27 pediatric patients with acute leukemia undergoing hematopoietic stem cell transplant.
A similar trend has been observed in adult patients. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
For the primary cataract endpoint of incidence of cataract development or cataract progression at Month 12, there was a greater proportion of subjects that experienced cataract development in the Kepivance group: A team of cyclists from sobi kepivsnce biked from mainz to brussels 24 october to help raise funds for people with haemophilia as well as awareness about the condition. Kepivance is supplied as a sterile, packzge, preservative-free, lyophilized powder for intravenous injection after reconstitution with 1.
A subset of subjects enrolled in the multiple myeloma study were included in an evaluation for the risk of cataract development in patients receiving Kepivance treatment. Palifermin for oral mucositis in the highdose chemotherapy and stem cell. Median 25 th75 th percentile Cumulative Opiod Dose morphine mg equivalents. With cancer treatment success comes a downsidemore disability and pain.
Kepivance is a water soluble, amino acid protein with a molecular weight of Use our drug profile search engine to kepivacne information about current Packate appproved cancer drugs.
California Cancer Care
Kepivance palifermin is a human keratinocyte growth factor kgf produced by recombinant dna technology in escherichia coli e coli. Historically, treatment for mucositis has consisted of supportive therapies, such as mouthwashes, aimed at reducing discomfort until the cells regenerate themselves, which takes about seven to 14 days.
Adverse events were similar to those reported in adult studies. There was no evidence of a delay in time to hematopoietic recovery in patients who received Kepivance as compared to patients who received placebo. Kepivance should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the fetus. The following adverse reactions have been identified during postapproval use of Kepivance in the stem cell transplant setting.
Istodax is a histone deacetylase hdac inhibitor indicated for. If you do not have the package insert for the drug you are using, your pharmacist or physician packagw be able to provide you with a copy. Drug Dictionary Details Use our drug profile search engine to review information about current FDA appproved cancer drugs.
Three age groups were studied: The safety and efficacy of Kepivance has not been established in patients with other types of cancer. Annals of Internal Medicine. Binding of KGF to its receptor has been reported to result in proliferation, differentiation, and migration of epithelial cells. Kepivance is a water soluble, amino acid protein with a. Case report successful use of palifermin following severe anaphylaxis to pegaspargase in a pediatric patient with acute lymphoblastic leukemia katie s kaminski1, cassidy l beach1, david b peden2,3.
The effect of palifermin on chemotherapyand radiation therapy. The KGF receptor has been reported to not be present on cells of the hematopoietic lineage. To view content sources and attributions, please refer to our editorial policy.